RVPH
NASDAQReviva Pharmaceuticals Holdings Inc.
Price$0.90-0.01 (-0.55%)
01:30 PM07:45 PM
News · 26 weeks43-33%
2025-10-262026-04-19
Mix2190d
- SEC Filings8(38%)
- Other7(33%)
- Offering3(14%)
- Insider2(10%)
- Analyst1(5%)
Latest news
25 items- PRReviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric IndicationsCUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on Monday, April 27, 2026 at 11:00 AM ET. The fireside chat will highlight the recent developments from Reviva's clinical stage drug candidate brilaroxazine and upcoming clinical, regulatory
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- PRReviva Announces Letter to ShareholdersCUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D. The full text of the letter follows. Dear Fellow Shareholders: The past year has been an important and challenging period for Reviva Pharmaceuticals. We have made difficult but necessary decisions to strengthen our capital position, preserve strategic flexibilit
- SECSEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- SECSEC Form S-8 filed by Reviva Pharmaceuticals Holdings Inc.S-8 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form 10-K filed by Reviva Pharmaceuticals Holdings Inc.10-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- PRReviva Reports Full Year 2025 Financial Results and Recent Business Highlights- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package highlights well-tolerated long-term safety profile, broad-spectrum clinical activity, and favorable adherence for once daily brilaroxazine up to one year - - Initiation of RECOVER-2 registrational trial planned in mid-2026 - CUPERTINO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (C
- SECSEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13D/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- PRReviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public OfferingCUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the closing on March 20, 2026 of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the "Series G Warrants") and Series H warr
- INSIDERSEC Form 4 filed by Prabhu Narayan4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
- INSIDERSEC Form 4 filed by Bhat Laxminarayan4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form 424B5 filed by Reviva Pharmaceuticals Holdings Inc.424B5 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- PRReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingCUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the "Series G Warrants") and Series H warrants to purchase u
- PRReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingCUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the of
- SECSEC Form 424B5 filed by Reviva Pharmaceuticals Holdings Inc.424B5 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- ANALYSTReviva Pharmaceuticals downgraded by D. Boral CapitalD. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- PRReviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in SchizophreniaFindings reinforce brilaroxazine's treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia CUPERTINO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the p
- PRReviva to Present at the Sachs 9th Annual Neuroscience Innovation ForumCUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA. Presentation Details: Format: Corporate PresentationDate: Sunday, January 11, 2026Time: 1:20 PM PTPresenter: Laxminarayan Bhat, Ph.D., Reviva PharmaceuticalsLocation: Marine